Skip to main content

siremadlin

Generic: Siremadlin

siremadlin: 2 clinical trials tracked.

siremadlin evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about siremadlin, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Acute Myeloid Leukemia

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (2)

A Phase Ib/II Open Label Dose Confirmation, Proof of Concept Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Unfit Adult AML Participants Who Responded Sub-optimally to First-line Venetoclax Plus Azacitidine Treatment and in Participants With Newly Diagnosed Unfit AML Presenting With High-risk Clinical Features

NCT05155709Registry updated 2026-05-07·Phase 1
Completed

Primary endpoint: Percentage of participants with Dose Limiting Toxicities (DLTs) as per investigator assessment reported during the first cycle (separately in Arm 1 & Arm 2)

Interventionalopen14 enrolledStarted 2022-05Completion 2024-0410 sites · Hong Kong, Hungary, Israel, Italy…Novartis Pharmaceuticals

A Multicenter, Phase I/II Study Evaluating the Clinical Impact of HDM201 + Pazopanib in Patients With P53 Wild-type Advanced/ Metastatic Soft Tissue Sarcomas (AMPHISARC)

NCT05180695Registry updated 2026-06-22·Phase 1/Phase 2
Active, not recruiting

Primary endpoint: for dose escalation part: the Maximum tolerated dose (MTD) of HDM201 given in combination with a fixed dose of pazopanib.

Interventionalopen47 targetStarted 2022-04Completion 2027-025 sites · FranceCentre Leon Berard